Literature DB >> 23129464

Case report: artificial elevation of prothrombin time by telavancin.

Derek F Amanatullah1, Matthew J Lopez, Robert C Gosselin, Munish C Gupta.   

Abstract

BACKGROUND: Methicillin-resistant Staphylococcus aureus infections are a well-documented risk of surgery and are becoming increasingly difficult to treat owing to continued acquired resistance. A new antibiotic for treatment of Staphylococcus aureus is telavancin. CASE DESCRIPTION: A patient at our institution was prescribed telavancin for multiple spinal abscesses before spinal surgery. Routine preoperative testing revealed an international normalized ratio (INR) of 2.05 with no clear cause. Careful review of the patient's medication history and prescriber information revealed that telavancin may interfere with prothrombin time (PT/INR) testing. In vitro testing by our laboratory confirmed an association between telavancin dose and an increase in PT/INR. An alternative reagent for PT/INR testing unaffected by telavancin dose revealed a PT/INR of 0.97. LITERATURE REVIEW: Telavancin interacts with artificial phospholipid surfaces used to monitor coagulation while having no actual effect on coagulation. PURPOSES AND CLINICAL RELEVANCE: All physicians, especially orthopaedic surgeons, should be aware of the effects of telavancin and ensure proper measures are taken to acquire the true INR by switching the reagent used to test PT/INR or ensuring the PT/INR is drawn before telavancin dosing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129464      PMCID: PMC3528902          DOI: 10.1007/s11999-012-2612-0

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  13 in total

1.  2009 FDA drug approvals.

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

2.  Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery.

Authors:  David H Kim; Maureen Spencer; Susan M Davidson; Ling Li; Jeremy D Shaw; Diane Gulczynski; David J Hunter; Juli F Martha; Gerald B Miley; Stephen J Parazin; Pamela Dejoie; John C Richmond
Journal:  J Bone Joint Surg Am       Date:  2010-07-07       Impact factor: 5.284

3.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control.

Authors:  M Nixon; B Jackson; P Varghese; D Jenkins; G Taylor
Journal:  J Bone Joint Surg Br       Date:  2006-06

5.  Telavancin.

Authors:  G Ralph Corey; Martin E Stryjewski; Wim Weyenberg; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

6.  Effects of telavancin on coagulation test results.

Authors:  S L Barriere; M R Goldberg; J W Janc; D L Higgins; P A Macy; D M Adcock
Journal:  Int J Clin Pract       Date:  2011-05-13       Impact factor: 2.503

7.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

8.  Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.

Authors:  Jeng-Pyng Shaw; Jonathan Cheong; Michael R Goldberg; Michael M Kitt
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

9.  Effect of telavancin (Vibativ) on routine coagulation test results.

Authors:  Robert Gosselin; William Dager; Aaron Roberts; Leslie Freeman; Lisa Gandy; Jeffrey Gregg; Denis Dwyre
Journal:  Am J Clin Pathol       Date:  2011-12       Impact factor: 2.493

10.  Telavancin: A novel lipoglycopeptide antibiotic.

Authors:  S E Damodaran; S Madhan
Journal:  J Pharmacol Pharmacother       Date:  2011-04
View more
  2 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.

Authors:  Michael P Ero; Nathaniel R Harvey; Jack L Harbert; James W Janc; Kay H Chin; Steven L Barriere
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.